articleThe LancetSep 22, 2016Closed access

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

NJNicholas J. VineyJCJulian C. van CapelleveenRSRichard S. GearySXShuting XiaJAJoseph A. Tami

Ionis Pharmaceuticals (United States) · Academic Medical Center · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

741
total citations
FWCI
85.16
Percentile
100%
References
39
Citations per year

Authors

14

Topics & keywords

Topics
Keywords
  • Tolerability
  • Medicine
  • Placebo
  • Apolipoprotein B
  • Population
  • Cohort
  • Lipoprotein(a)
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.